 |
LE-MONT-SUR LAUSANNE, Switzerland, September 13, 2018 /PRNewswire/ —
Mr. Antoine Turzi, inventor, Regen Lab SA and RegenLab USA LLC are delighted to announce that the United States Patent and Trademark Office (USPTO) has issued two new U.S. patents covering its Platelet Rich Plasma (PRP), Bone Marrow Concentrate (BMC) and Hyaluronic Acid (HA) technologies:
- Systems/methods combining PRP and HA: U.S. Patent No. 10,052,349 and
- Systems for the preparation of PRP and BMC, in particular tubes containing a thixotropic gel and anticoagulant: U.S. Patent No. 10,064,894.
This brings a total of six U.S. granted patents with US8,529,957, US9,833,478, US9833478, US8,945,537 and US9,517,255 on these technologies, expanding RegenLab’s patent portfolio along with patents also recently granted in other jurisdictions (see figure below).
All these new patents represent a recognition by the USPTO of RegenLab’s innovation, technology and efficiency. This is great news for RegenLab, its employees and partners, and justifies that RegenLab maintains its legal actions for the respect of its intellectual property rights. The stars are shining for RegenLab’s team and its future.
About RegenLab
RegenLab is a leading innovator of medical devices for the preparation of platelet rich plasma, which it markets under the well-recognized REGENLAB® and REGENKIT® brands. RegenLab remains committed to providing pyrogen-free devices of the highest quality and safety, as well as protecting customers through enforcement of its intellectual property rights.
Additional information about RegenLab and its patents can be found at https://www.regenlab.com/patents and http://www.RegenLabUSA.com.
